Phagocytic activity and the phagocytic index of milk PMN’s as a marker for diagnosis and monitoring of the therapeutic and prophylactic efficacy of antioxidant formulation in bovine mastitis

Amatul Muhee, Hamidullah Malik, Riyaz A. Bhat*, Syed Taifa, Mehak N. B. Azad, and Waseem Rather

Division of Clinical Veterinary Medicine, Ethics and Jurisprudence, Faculty of Veterinary Sciences and Animal Husbandry, Srinagar, Jammu and Kashmir, India

ABSTRACT

A clinical study was undertaken on bovine mastitis in the Kashmir valley to study the relationship between Phagocytic activity (PA) and the phagocytic index (PI) of milk neutrophils (PMN’s) and bovine mastitis. The PA and PI of milk PMN’s were assessed in mastitic animals and compared with normal, healthy, lactating animals. A significant decrease was found in the values of the PA and PI of milk neutrophils in clinical cases of mastitis as compared to the healthy control group. The utility of anti-oxidants in clinical management of mastitis was measured through the response to treatment with trace minerals such as Cu, Zn, Mn and Se in addition to conventional antibiotic therapy. Two groups of mastitic animals received two therapeutic regimens. Group I animals received antibiotics (Enrofloxacin 6.6 mg/kg BID for 5 days) and a self-formulated trace mineral anti-oxidant mixture at therapeutic doses for 7 days, while Group II animals only received the antibiotic (at the same dose rate and frequency). Therapeutic regimen I proved more efficacious than the therapeutic regimen II in the treatment of clinical mastitis, as evidenced by higher recovery rates, a lower number of mean days required for recovery, and higher PA and PI of the milk PMN’s on day 10 post treatment. For prophylactic studies, 24 healthy lactating cows were divided into two groups of 12 animals each. One group was supplemented with a self-formulated trace mineral anti-oxidant mixture at prophylactic doses for 30 days, which resulted in a significant improvement in udder health status in terms of the SCC, PA and PI of milk PMN’s. Supplementation with the antioxidant formulation played a significant role in early recovery and prophylaxis of bovine mastitis. Assessment of PA and PI of milk PMN’s could be utilised as an effective tool for diagnosing susceptibility to the occurrence of mastitis, as well as monitoring the therapeutic efficacy of different treatment regimes.

Key words: bovine mastitis; milk PMN’s; phagocytic activity; phagocytic index; anti-oxidant trace minerals

*Corresponding author:
Dr. Riyaz Ahmed Bhat, Division of Clinical Veterinary Medicine, Ethics and Jurisprudence, Faculty of Veterinary Sciences and Animal Husbandry, Srinagar-190006, Jammu and Kashmir, India, E-mail: koolriya22@gmail.com
A. Muhee et al.: Phagocytic activity and the phagocytic index of milk PMN’s as a marker for diagnosis and monitoring of the therapeutic and prophylactic efficacy of antioxidant formulation in bovine mastitis

Introduction

Mastitis is a difficult problem to comprehend because of its multifactorial infectious nature. Its incidence depends on the microorganisms involved, the surrounding environment and the defense mechanisms in the udder tissues and blood. The mammary gland is protected by a variety of defense mechanisms, such as non-phagocytic and phagocytic defences (ATABAI et al., 2007; MEHRZAD et al., 2010). The phagocytic defence consists mainly of phagocytic cells in the mammary gland and those recruited in response to inflammatory reactions (PMNs/Neutrophils). Neutrophils form the integral part of mammary innate defense system during foreign intrusion of microbes as an early response of the host body (BORREGAARD, 2010). The ability of neutrophils to phagocytose foreign particles is important for protection of the mammary gland, and in vitro analysis of neutrophil function provides a very effective tool for the study of natural mastitis resistance (AL HUSSSEIN et al., 2015). It has been reported that the main reason for the increased susceptibility in dairy animals to mastitis is immune-suppression (MALLARD et al., 1998). Successful intramammary defence is dependent on an increase in PMN arriving at the site of infection and a high rate of phagocytosis (PAAPE et al., 2003). Any condition that depresses PMN functions adversely affects the udder’s resistance to invasive infections (MEHRZAD et al., 2009). The increased incidence of severe mastitis during early lactation correlates with decreased blood and milk PMN (MEHRZAD et al., 2010), further emphasizing the pivotal role of PMN in the defence against intramammary pathogens. Phagocytic activity (PA) is the percentage of neutrophils that phagocytosed the target organisms in an in vitro condition, and the phagocytic index (PI) is calculated as the average number of target microorganism(s) phagocytosed per phagocyte. Although the phagocytic ability of the milk neutrophils in the mammary gland is lower than in other tissues, it still remains the most critical defense once the teat end barrier is breached. The circulating half-life of neutrophils is about 6 hours, so the cow replaces half of those cells every 6 hours from its bone marrow stores, and the circulating pool is largely dependent on the proliferative capacity of the bone marrow (KIMURA et al., 1999). Clearly, a significant component of the dietary energy and protein consumption for maintenance is spent on replenishment of immune cells. So, supplementing trace minerals and vitamins in greater quantity in and around parturition reduces both the duration and the severity of udder affections, and enhances udder immunity (WEISS, 2002). So the best way to treat mastitis is to give mastitic cows the best possible hygienic conditions and an appropriate diet. It has been proved that dietary supplementation with high levels of Vitamin E during the periparturient period substantially benefits udder health (BOUWSTRA et al., 2010) and enhances the chemotactic responsiveness of blood neutrophils (EICHER et al., 1994). Enhanced phagocytic activity and phagocytic index have also been reported in milk PMN cells in mastitic buffaloes treated with enrofloxacin, vitamin E and selenium (MUKHERJEE, 2008). Supplementation with antioxidants may prove an effective tool for protecting mammary tissue against PMN-induced oxidative stress during bovine mastitis, and in addition antioxidant supplementation may also help in preventing mastitis by strengthening the mammary defense system and improving immunity. So the present study was undertaken to study the effect of supplementation of anti-oxidant trace minerals on the clinical recovery, prophylaxis, and phagocytic activity and phagocytic index of milk PMN’s in bovine mastitis. The role of the PA and PI of milk PMN’s as diagnostic and prophylactic markers of bovine mastitis was also evaluated.

Materials and methods

The study was undertaken on clinical cases of bovine mastitis presented for treatment to the Teaching Veterinary Clinical Complex, F.V.Sc & A.H, SKUAST-K and local animal husbandry dispensaries in the areas of Ganderbal, Manasbal, Shuhama, Gulab Bagh and Shalimar during the course of study.

A total of 36 multiparous cows in the 4-8 years age group with body condition score (BCS) 3.0, were included for the study. Twenty-four cows among them had clinical mastitis, 12 apparently healthy lactating animals served as a control group,
and no experimental case was included. The cases of clinical mastitis were diagnosed on the basis of clinical examination, case history and clinical findings. The severity of the cases was assessed on the basis of CMT score and SCC of milk samples. Cases with a CMT score of 2 or 3, with somatic cell counts higher than $4 \times 10^5$ /mL of milk were considered positive for mastitis.

For performing therapeutic trials, the mastitic animals were diagnosed by clinical presentation, CMT score and SCC, and were further divided into two groups of twelve animals each. The animals in group I were given a self-formulated anti-oxidant trace mineral mixture at therapeutic doses, as recommended by NRC, 2001, whose formulation is given in Appendix 1. All four ingredients were mixed together, making a total weight of about 5.005 g, and stored in air-tight, zip lock, polythene pouches. A total of 7 pouches were given to individual animal owners so they could provide the contents of one pouch to the animals once daily for 7 days. Group II animals were not given any anti-oxidant trace mineral mixture. Both the groups of animals were given the antibiotic enrofloxacin at the dose rate of 6.6 mg/kg i/m per animal, twice daily for 5 days. The choice of the antibiotic was based on an antibiotic sensitivity test of the milk, which was performed in each case. Animals found to be insensitive to enrofloxacin were excluded from the study. The therapeutic trial design for the cows with clinical mastitis is provided in Table 1.

For the prophylactic study, 24 recently parturiated, lactating animals maintained at the Mountain Livestock Research Institute (MLRI), SKUAST-K, Manasbal, under similar managemental conditions, but with susceptibility to occurrence of mastitis (as evidenced by precedence to occurrence of mastitis in previous lactations) were selected. One group of animals (Group I) comprised of 12 animals, received a self-formulated anti-oxidant trace mineral mixture for a period of thirty days, while Group II also comprised of 12 animals did not receive any anti-oxidants. The anti-oxidant trace minerals were given at prophylactic doses as recommended by NRC, 2001. The composition of the anti-oxidant trace mineral mixture is given in Appendix 1. The total dose per animal was 1.402 grams. Three hundred and sixty pouches were made, and one pouch per animal per day was given to Group I animals for 30 days.

The efficacy of the prophylactic treatment was evaluated by registering the occurrence of mastitis during the course of the therapy and one month after therapy. The udder health status of both the groups of animals was assessed on the basis of an estimation of the SCC of the milk, phagocytic activity and the phagocytic index of the milk PMN’s day 0, day 15 and day 30 of treatment, and fifteen days after the end of the treatment. Both groups of animals were monitored for the occurrence of mastitis for a period of one month after the end of the therapy.

Table 1. Therapeutic trial design for cows with clinical mastitis

<table>
<thead>
<tr>
<th>Group</th>
<th>No. of animals treated</th>
<th>Treatment</th>
<th>Dosage</th>
<th>Route</th>
<th>Frequency</th>
<th>Duration of treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group I (Therapeutic regime I)</td>
<td>12</td>
<td>Inj. Enrofloxacin</td>
<td>6.6 mg/kg</td>
<td>I/M</td>
<td>BID</td>
<td>5 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Anti-oxidant trace mineral mixture</td>
<td>5.005 gms</td>
<td>Oral</td>
<td>OD</td>
<td>7 days</td>
</tr>
<tr>
<td>Group II (Therapeutic regime II)</td>
<td>12</td>
<td>Inj. Enrofloxacin</td>
<td>6.6 mg/kg</td>
<td>I/M</td>
<td>BID</td>
<td>5 days</td>
</tr>
</tbody>
</table>
The phagocytic activity of the milk PMN’s was estimated from the milk of healthy lactating cows as well as from clinical cases of mastitis on day 0, day 5 and day 10 of treatment and for prophylactic studies on day 0, day 15 and day 30 of treatment. The in vitro phagocytosis activity of milk neutrophils (PMN) was determined on Staphylococcus aureus. The procedure was performed in the following manner:

**Isolation of milk PMN’s.** A total of 50 mL of milk was passed through cheese cloth and then poured into 50 mL conical tubes and centrifuged in a cooling centrifuge at 1200g or 2942 rpm (approximately 3000) at 4 °C. The fat was removed and the skim milk was poured off and discarded. The cell pellet was washed twice in cold Dulbecco’s PBS and centrifuged at 1000 rpm for 10 minutes and 200g for 15 minutes at 4 °C and resuspended in Dulbecco’s PBS containing 0.5mg/mL gelatin. In a 15 mL falcon, 3mL of Histopaque 1119 (Sigma Aldrich, USA) was taken, over which 3 mL of Histopaque 1077 (Sigma Aldrich, USA) was layered slowly so as to form a ring at the junction of the two histopaques. Three mL of cell suspension was layered slowly over the Histopaque 1077. The tube was gently placed into the centrifuge and centrifugation was carried out at 2000 g at 4 °C for 30 minutes. The cell pellet formed at the interface between the Histopaque 1119 and 1077 was taken as the milk PMN’s. The collected cells were washed twice with PBS and resuspended in RPMI medium containing 0.5% fetal calf serum for further analysis, and they served as the source of milk PMN’s. The viability of milk PMN’s was checked by the trypan blue exclusion technique, and the final cell concentration was adjusted to 1×10^6 cells/mL.

**Viable cell count of milk leukocytes.** Before the cells had the chance to settle, 0.5 mL of cell suspension was transferred into an Eppendorf tube.100 µL of cells were transferred into a new Eppendorf tube, 400 µL of 0.4% trypsin blue was added and gently mixed. One hundred µL of trypsin blue treated cells were loaded onto a haemocytometer. The viable (unstained) cells were counted in all the four sets of 16 corners (WBC counting chambers).Viable cell count was expressed as:

Viable cell count = Average count in 4 squares × Dilution factor ×10^4

% Viability = All live and dead cells were added to obtain the total cell count. The live cell count was divided by the total cell count to calculate the viability percentage.

Dilution factor = 5

Viability of all the samples was more than 90%.

**Adjustment of cell numbers.** The concentration in the cell suspension was adjusted to 2.5×10^6 cells/mL.

\[ X \text{ mL of RPMI added} = \frac{\text{No. of viable cells per mL}}{2.5 \times 10^6} \]

(e.g., if the viable cell count was 5×10^6, X-1 mL of RPMI i.e. 2 -1 = 1 mL of RPMI was added to PMN suspension to reach a concentration of 2.5×10^6 cells/mL).

**Phagocytic activity and phagocytic index.** Bacterial concentration of 18hour culture of pure Staphylococcus aureus (MTCC, Chandigarh) was adjusted to 2 ×10^8 cfu/mL by checking optical density (OD) at 540 nm under a UV spectrophotometer (OD was adjusted to 0.6 with PBS). For phagocytosis assay, 0.1 mL of the bacterial suspension was opsonised with 0.1 mL of pooled bovine serum in an incubator at 37 °C for 1 hour, in a tissue culture plate. Then 0.8 mL of PMN suspension was added and incubated at 37 °C for 30 minutes to maintain the PMN’s and bacteria in a ratio of 1:10. Smears were prepared and stained with Leishman stain. The slides were then examined under a high power microscope at ×1000 magnification.

PA (phagocytosis percentage) was estimated as the percentage of cells that took part in phagocytosis

\[ \text{Phagocytic activity} = \frac{\text{No. of PMN that engulfed bacteria}}{\text{No. of PMN counted}} \times 100 \]

Phagocytic index (PI) was estimated as the mean of the total bacteria counted phagocytosed per neutrophil.

\[ \text{Phagocytic index} = \frac{\text{Total bacteria in N neutrophil}}{N} \]

There was 25 neutrophils counted 25, so here N = 25.
The result of PA was reported as the percentage (%) of phagocytosing neutrophils counting 100 PMN cells in different microscope fields, and the result of PI was reported as the average number of bacteria per neutrophil.

Statistical analysis. The data was analysed using statistical tools (SPSS version 20). ANOVA followed by Duncan’s multiple range test were used for multiple comparisons. The paired ‘t’ test was used for pre- and post-treatment comparisons within each treatment group. Repeated measure ANOVA was used for multiple pre- and post-treatment comparisons. Statistical differences were determined at the level of 5% significance.

Results

Phagocytic activity and the phagocytic index of milk neutrophils or PMN’s. The phagocytic activity (PA) and phagocytic index (PI) of milk neutrophils or PMN’s in the healthy control group and in animals with clinical mastitis (mastitic group) is presented in Table 2. The effect of the different therapeutic regimens (I & II) on the phagocytic activity and phagocytic index of milk neutrophils in the two groups of mastitic animals (Group I and Group II) is presented in Table 3. The mean values for the phagocytic activity of milk neutrophils (%) in the healthy control group of animals (35.42 ± 1.27) was significantly higher (P<0.05) than that of the mastitic group values (18.30 ± 0.46), as shown in Table 2. The mean values for the phagocytic activity of neutrophils (%) in group I animals with clinical mastitis were 18.13 ± 0.58, 23.07 ± 0.78 and 33.47 ± 1.08 on day 0, day 5 and day 10 of receiving therapeutic regimen I, respectively (Table 3). The mean values of the phagocytic activity of milk neutrophils (%) on days 0, 5 and 10 of treatment within group I mastitic animals differed significantly from each other (P<0.05). In group II animals with clinical mastitis, the mean values of the phagocytic activity of milk neutrophils (%) on days 0, 5 and 10 of treatment with therapeutic regimen II were 18.5 ± 0.76, 24 ± 0.95 and 28.25 ± 0.83, respectively, and also differed significantly (P<0.05) from each other (Table 3). The mean value of PI in the healthy control group was 6.82 ± 0.16, while in mastitic group the mean value was 3.64 ± 0.10 (Table 2). The difference in the mean values of PI between the healthy control group and the mastitic group was statistically significant (P<0.05). The mean values for the PI of neutrophils in group I animals with clinical mastitis were 3.65 ± 0.14, 5.33 ± 0.14 and 6.26 ± 0.07 on days 0, day 5 and day 10 of treatment, respectively, and the mean values of the phagocytic index of neutrophils on days 0, 5 and 10 of treatment within this group of mastitic animals differed significantly (P<0.05%) from each other (Table 3). In group II animals with clinical mastitis the mean values were 3.62 ± 0.16, 4.86 ± 0.17 and 5.79 ± 0.20 on day 0, day 5 and day 10 of treatment, respectively, and the mean values of the phagocytic index of neutrophils on days 0, 5 and 10 within this group of animals also differed significantly (P<0.05%) from each other (Table 3).

Recovery of animals. In group I animals, ten animals recovered within a mean 4 ± 0.5 days, as evidenced by clinical recovery (CMT negative), and the return of milk SCC and milk chemistry parameters to normal.

Table 2. Comparison of Phagocytic activity (PA) and Phagocytic Index (PI) between healthy lactating (control group) and mastitic animals

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Control Group (n = 12)</th>
<th>Mastitic Group (n = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phagocytic Activity (%)</td>
<td>35.42 ± 1.27&lt;sup&gt;a&lt;/sup&gt;</td>
<td>18.30 ± 0.46&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>Phagocytic Index (average No. of bacteria phagocytosed per phagocyte)</td>
<td>6.82 ± 0.16&lt;sup&gt;c&lt;/sup&gt;</td>
<td>3.64 ± 0.10&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Values within a row with a superscript (a,b) with at least one common letter do not differ significantly at the level of 5% (P<0.05) from each other.
A. Muhee et al.: Phagocytic activity and the phagocytic index of milk PMN’s as a marker for diagnosis and monitoring of the therapeutic and prophylactic efficacy of antioxidant formulation in bovine mastitis

Table 3. Effect of treatment on Phagocytic Activity (PA) and Phagocytic Index (PI) in animals with clinical mastitis

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Days of treatment</th>
<th>Group I (Antibiotic + Antioxidant trace minerals)</th>
<th>Group II (Antibiotic only)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Phagocytic Activity (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 0</td>
<td>18.13 ± 0.58a</td>
<td>18.50 ± 0.77a</td>
</tr>
<tr>
<td></td>
<td>Day 5</td>
<td>23.07 ± 0.78b</td>
<td>24.00 ± 0.96b</td>
</tr>
<tr>
<td></td>
<td>Day 10</td>
<td>33.47 ± 1.08c</td>
<td>28.25 ± 0.83c</td>
</tr>
<tr>
<td>Phagocytic Index (Average No. of bacteria phagocytosed per phagocyte)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 0</td>
<td>3.65 ± 0.14a</td>
<td>3.62 ± 0.16c</td>
</tr>
<tr>
<td></td>
<td>Day 5</td>
<td>5.33 ± 0.14b</td>
<td>4.86 ± 0.17b</td>
</tr>
<tr>
<td></td>
<td>Day 10</td>
<td>6.26 ± 0.07c</td>
<td>5.79 ± 0.20c</td>
</tr>
</tbody>
</table>

Values within a column having superscript (a,b,c) with at least one common letter do not differ significantly at the level of 5% (P<0.05) from each other.

Table 4. Therapeutic efficacy of treatment regimes in animals with clinical mastitis

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Group I</th>
<th>Group II</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animals treated</td>
<td>12</td>
<td>12</td>
</tr>
<tr>
<td>Animals recovered</td>
<td>10</td>
<td>8</td>
</tr>
<tr>
<td>% Recovery</td>
<td>83.33%</td>
<td>66.66%</td>
</tr>
<tr>
<td>Recovery time (Days ± S.E)</td>
<td>4 ± 0.5</td>
<td>4.5 ± 0.8</td>
</tr>
</tbody>
</table>

Table 5. Impact of prophylactic anti-oxidant trace mineral therapy on udder health status of healthy lactating animals during treatment

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Days of treatment</th>
<th>Group I (With anti-oxidants)</th>
<th>Group II (Without anti-oxidants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCC (×10⁵/mL)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 0</td>
<td>2.81 ± 0.07⁴¹</td>
<td>2.81 ± 0.06⁴²</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>2.65 ± 0.06⁴¹</td>
<td>2.77 ± 0.06⁴¹,²</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>2.48 ± 0.03⁴²</td>
<td>2.97 ± 0.07⁴²²</td>
</tr>
<tr>
<td>Phagocytic Activity (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 0</td>
<td>28.13 ± 0.58⁴¹</td>
<td>28.50 ± 0.77⁴¹¹</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>31.07 ± 0.78⁴²</td>
<td>24.00 ± 0.96⁴²²</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>35.47 ± 1.08⁴³</td>
<td>28.25 ± 0.83³⁴¹,³</td>
</tr>
<tr>
<td>Phagocytic Index (Average No. of bacteria phagocytosed per phagocyte)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Day 0</td>
<td>3.65 ± 0.14⁴¹</td>
<td>3.62 ± 0.16⁴¹</td>
</tr>
<tr>
<td></td>
<td>Day 15</td>
<td>5.83 ± 0.14⁴²</td>
<td>4.06 ± 0.17⁴²²</td>
</tr>
<tr>
<td></td>
<td>Day 30</td>
<td>6.96 ± 0.07⁴³</td>
<td>4.79 ± 0.20⁴²²</td>
</tr>
</tbody>
</table>

Values within a row with a superscript (a,b) with at least one common letter do not differ significantly at the level of 5% (P<0.05) from each other. Values within a column with a (1,2,3) with at least one common number do not differ significantly at the level of 5% (P<0.05) from each other.
A. Muhee et al.: Phagocytic activity and the phagocytic index of milk PMN’s as a marker for diagnosis and monitoring of the therapeutic and prophylactic efficacy of antioxidant formulation in bovine mastitis

The percentage recovery was 83.33%. Group II animals were not given any mineral mixture. In this group of animals, 12 animals were treated, of which 8 animals recovered completely within a mean 4.5 ± 0.8 days, as evidenced by clinical recovery (CMT negative) and the return of milk SCC and milk biochemical parameters to normal. The percentage recovery was 66.66%.

**Prophylactic studies.** The udder health status of both groups of animals was monitored through estimation of the somatic cell count and phagocytic activity, and the phagocytic index of neutrophils on days 0, 15 and 30 during the course of treatment, as well as 15 days after the end of the treatment (Tables 5 and 6). The animals were monitored for 15 more days, *i.e.* for a total period of one month after stopping the treatment, for occurrence of mastitis. Milk SCC was lower and the phagocytic activity of the milk PMN’s was significantly higher in the group I animals as compared to group II animals, as shown in Tables 5 and 6. Clinical mastitis was not observed in any of the animals in the two groups of animals, either during the course of treatment or one month after the study.

**Table 6. Impact of prophylactic anti-oxidant trace mineral therapy on the udder health status of healthy lactating animals 15 days after stopping the therapy**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group I (With anti-oxidants)</th>
<th>Group II (Without anti-oxidants)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCC (∗10⁵/mL)</td>
<td>2.72 ± 0.09⁵⁺</td>
<td>3.07 ± 0.06⁶⁺</td>
</tr>
<tr>
<td>Phagocytic Activity (%)</td>
<td>38.40 ± 1.25⁴⁺</td>
<td>29.90 ± 0.72⁵⁺</td>
</tr>
<tr>
<td>Phagocytic Index(Average No. of bacteria phagocytosed per phagocyte)</td>
<td>7.26 ± 0.09⁴⁺</td>
<td>5.57 ± 0.19⁵⁺</td>
</tr>
</tbody>
</table>

Values within a row with a superscript (a,b) with at least one common letter do not differ significantly at the level of 5% (P<0.05) from each other.

**APPENDIX -I: Therapeutic dose of mineral mixture:**
- Copper sulphate: 1 gm.
- Zinc sulphate: 2 gm.
- Manganese sulphate: 2 gm
- Selenium: 5 mg
- Total Dose: 5.005g/animal/day for 7 days

**APPENDIX -II: Prophylactic dose of mineral mixture:**
- Copper sulphate: 500 mg
- Zinc sulphate: 500 mg
- Manganese sulphate: 400 mg
- Selenium: 2 mg
- Total Dose: 1.042 g/animal/day for 30 days

![Fig. 1. Phagocytic activity of milk PMN’s](image1)

![Fig. 2. Phagocytic index of milk PMN’s](image2)
Discussion

Phagocytic activity and phagocytic index of milk neutrophils or PMN’s. Our findings of decreased phagocytic activity and lower phagocytic index in clinical mastitis are in agreement with the findings of AL-HUSSEIN et al. (2015), who also reported a significant decrease in phagocytic activity of milk PMN’s in cows with clinical and sub-clinical mastitis. Our findings are also in agreement with DE UK and MUKHERJEE (2013), who also found that the PA of milk leukocytes was lower in mastitic cows, whereas, a significant enhancement in PA was recorded in post-treated cows. PICCININI et al. (1999) also reported depressed milk PMN phagocytic activity associated with intramammary infection by S. aureus.

Recovery of animals. Our findings of increased recovery in group I animals are supported by the fact that dairy cows supplemented with a combination of anti-oxidant trace elements (Se, Cu, Zn and Mn) in therapeutic regimen I vs. therapeutic regimen II showed better recovery rates (83.33% vs 66.66%), a shorter recovery time (4 ± 0.5 days vs. 4.5 ± 0.8 days) with higher phagocytic activity and phagocytic index of the milk PMN’s. Our findings of increased recovery rates through the use of anti-oxidant trace mineral supplementation is supported by the findings of MACHADO et al. (2013). YANG and LI (2015) also reported that supplementation of mastitic dairy cows with antioxidant vitamins such as vitamin A, C, E and β-carotene, and antioxidant minerals such as selenium, zinc and copper was very important to help the animals recover early.

Prophylactic studies. The udder health status of group I animals was found to be better than group II as evidenced by a significant increase in phagocytic activity and the phagocytic index of their milk PMN’s, and the significant decrease in milk SCC count during the course of treatment and 15 days after the end of treatment (Tables 5 and 6), indicating the increased capability of the udders to defend themselves against the attack of the pathogenic microorganisms responsible for causing mastitis, and hence the decreased susceptibility to the occurrence of mastitis in this group as compared to the control group. Our findings are in agreement with MACHADO et al. (2013) who reported that dairy cows supplemented with a combination of different trace elements (Se, Cu, Zn and Mn) showed lower SCC levels (decreased incidence of mastitis) in comparison to the control cows. SORDILLO and MAVANGIRA (2014) also advocated controlling mastitis through appropriate antioxidant supplementation in the form of trace mineral supplementation that could potentially boost the animals’ health status and performance.

Conclusion

Since the present study revealed significantly lower PA and PI of milk PMN’s in clinical mastitis, which subsequently increased with supplementation of an antioxidant mineral formulation, estimation of the PA and PI of milk PMN’s may prove to be an effective biomarker for detecting susceptibility to the occurrence of bovine mastitis, and monitoring the therapeutic efficacy of treatment regimes. Anti-oxidant trace minerals such as Cu, Zn, Mn and Se significantly increase the PA and PI of milk PMN’s, and thereby aid early recovery from bovine mastitis and play a significant role in prophylaxis of mastitis in lactating animals. This study strongly supports the hypothesis that boosting the PA and PI of milk PMN’s through supplementation with an anti-oxidant mineral mixture could prove an effective strategy to prevent and reduce the severity of bovine mastitis.

Acknowledgment

The authors are highly thankful to FVSc and AH, Shuhama for providing the necessary facilities for this research work.

Conflict of interest

The authors declare that there is no conflict of interest for this study.

References


A. Muhee et al.: Phagocytic activity and the phagocytic index of milk PMN’s as a marker for diagnosis and monitoring of the therapeutic and prophylactic efficacy of antioxidant formulation in bovine mastitis


DOI: 10.3168/jds.2010-3159


DOI: 10.1016/j.rvsc.2013.06.010


DOI: 10.3168/jds.s0022-0302(94)76984-8


DOI: 10.3168/jds.s0022-0302(99)75489-5


DOI: 10.1016/j.tvjl.2013.02.022


DOI: 10.1017/s0022029999003751


DOI: 10.1071/an14503


DOI: 10.5455/javar.2015.b48

Received: 16 May 2020
Accepted: 5 June 2020


SAŽETAK

Kliničko istraživanje mastitisa goveda u dolini Kashmir provedeno je kako bi se procijenila povezanost fagocitne aktivnosti (PA) i fagocitnih indeksa (PI) neutrofila u mlijeku (PMN’s) i mastitisa goveda. PA i PI neutrofila u mlijeku analizirani su u životinja s mastitisom i uspoređeni sa zdravim životinjama u laktaciji. Pronađeno je znakovito smanjenje PA i PI neutrofila u mlijeku u slučajevima mastitisna goveda, a u usporedbi s kontrolnim, zdravom skupinom. Korisnost
A. Muhee et al.: Phagocytic activity and the phagocytic index of milk PMN's as a marker for diagnosis and monitoring of the therapeutic and prophylactic efficacy of antioxidant formulation in bovine mastitis

antioksidansa u slučajevima kliničkog mastitisa mjerena je putem odgovora na liječenje mineralima u tragovima kao što su Cu, Zn, Mn i Se, koji su dodani konvencionalnoj antibiotskoj terapiji. Dvije skupine životinja s mastitisom imale su dva terapijska programa. Skupina 1 primala je antibiotik (enrofloksacin 6,6 mg/kg, 2 puta dnevno, tijekom 5 dana) i vlastito pripremljenu mješavinu antioksidantnih minerala u tragovima u terapijskoj dozi tijekom 7 dana, dok je skupina 2 dobivala samo antibiotike (u istoj dozi i intervalu). Terapijski program u skupini 1 pokazao se učinkovitijim od onoga u skupini 2 u liječenju kliničkog mastitisa, što dokazuju veće stope oporavka, manji prosječan broj dana potreban za oporavak te povećane vrijednosti PA i PI polimorfonuklearnih stanica mlijeka deseti dan poslije tretmana. Za istraživanje profilakse 24 zdrave krave u laktaciji podijeljene su u dvije skupine sa po 12 životinja. Jedna je skupina dobivala vlastito pripremljenu mješavinu antioksidantnih minerala u tragovima u profilaktičkoj dozi tijekom 30 dana. To je rezultiralo znakovitim poboljšanjem zdravlja vimenja što se vidjelo po vrijednostima SCC, PA i PI neutrofila u mlijeku. Dodatak antioksidantne formulacije znakovito je utjecao na rani oporavak i profilaksu mastitisa u goveda. Procjena PA i PI polimorfonuklearnih stanica mlijeka mogla bi biti učinkovit alat pri dijagnostici sumnje na mastitis kao i praćenju učinkovitosti različitih terapijskih program.

Ključne riječi: mastitis goveda; polimorfonuklearne stanice mlijeka; fagocitna aktivnost; fagocitni indeksi; antioksidantni minerali u tragovima